ClearNote Health is heading to the American Association for Cancer Research Annual Meeting, 2026.
📍 Booth #3448
Across oncology, two challenges continue to dominate conversations:
• the rising cost and inefficiency of drug development
• the need for earlier cancer detection to improve patient outcomes and healthcare economics
At the core of both is a deeper understanding of cancer biology.
At AACR, we’ll be highlighting the power of 5hmC epigenomics to reveal active disease biology from a simple blood draw.
Our platforms are designed to support teams across the research and clinical continuum:
🔬 Virtuoso™ – delivering epigenomic insights to support oncology drug discovery and development
🩸 Avantect® – a blood-based test designed to enable earlier detection of pancreatic cancer, when intervention may be most effective
If you’re attending AACR, stop by booth #3448 to learn more about how 5hmC epigenomics can support discovery and early detection.
Schedule a meeting in advance: [email protected]